GLP-1 Agonists: What They Are, How They Work & Side Effects
WEBJul 3, 2023 · GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity. GLP-1 agonists are most often injectable medications, meaning you inject a liquid medication with a needle and syringe.
Glucagon-like peptide-1 - Wikipedia
WEBGlucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from the tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption.
Glucagon-Like Peptide-1 Receptor Agonists - StatPearls - NCBI Bookshelf
WEBFeb 29, 2024 · Glucagon-like peptide-1 (GLP-1) agonists are a class of medications utilized to treat type 2 diabetes mellitus (T2DM) and obesity. As a class of medications, they are among several pharmacological options for these endocrine diseases.
Glucagon-like peptide 1 (GLP-1) - PMC - National Center for ...
WEBSep 30, 2019 · The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β …
Glucagon-like peptide 1-based therapies for the treatment of ... - UpToDate
WEBAug 26, 2024 · Glucagon-like peptide 1 (GLP-1)-based therapies (eg, GLP-1 receptor agonists, dual-acting GLP-1 and glucose-dependent insulinotropic polypeptide [GIP] receptor agonists, dipeptidyl peptidase 4 [DPP-4] inhibitors) affect glucose control through several mechanisms, including enhancement of glucose-dependent insulin secretion, slowed gastric ...
Glucagon-like peptide 1 (GLP-1) - PubMed
WEBBiochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity.
Metabolic Messengers: glucagon-like peptide 1 - Nature
WEBJan 11, 2021 · Glucagon like peptide-1 (GLP-1), a peptide hormone from the intestinal tract, plays a central role in the coordination of postprandial glucose homeostasis through actions on insulin...
Glucagon-like peptide 1 in health and disease - Nature
WEBMay 4, 2018 · In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates insulin release and suppresses glucagon secretion in response to the ingestion of nutrients. GLP1 also...
Recent advances in understanding the role of glucagon-like peptide 1
WEBApr 6, 2020 · Glucagon-like peptide 1 (GLP-1) was initially identified as a gut-derived incretin hormone that augments insulin secretion in a glucose-dependent manner from pancreatic islet beta cells during the postprandial period 1, 2.
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
WEBGlucagon-like peptide-1 (GLP-1) has emerged as a gut-derived peptide with pleiotropic actions and has demonstrated therapeutic efficacy for cardiometabolic disorders, principally diabetes and obesity.
Skip to content